VOR BIOPHARMA INC (VOR) Stock Earnings & Estimates
NASDAQ:VOR - US9290331084 - Common Stock
2 USD
-0.04 (-1.96%)
2.0197 USD
+0.02 (+0.98%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 141.04% | N/A 265.42% | N/A 67.41% | N/A 106.01% | N/A 20.51% | ||||||||
| EBITDA YoY % growth | -2.84M | -10.33M -263.73% | -42.76M -313.94% | -67.59M -58.07% | -90.89M -34.47% | -122.544M -34.83% | -117.657M 3.99% | N/A -6.71% | N/A -15.75% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -2.86M | -10.42M -264.34% | -43.37M -316.22% | -69.02M -59.14% | -93.42M -35.35% | -126.036M -34.91% | -121.185M 3.85% | N/A -68.60% | N/A 60.25% | N/A -56.65% | N/A 77.27% | N/A 447.38% | N/A 139.88% | N/A 133.59% | N/A 24.51% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.15 85.44% | -2.34 -8.84% | -1.76 24.79% | -1.70 3.41% | N/A 26.21% | N/A 71.82% | N/A -190.48% | N/A 84.26% | N/A 143.75% | N/A 347.57% | N/A 174.50% | N/A 27.33% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.11 73.59% | -0.09 79.20% | -0.10 60.77% | -0.10 95.46% | -0.10 1.05% | -0.10 -7.62% |
| Revenue Q2Q % growth | ||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -21.439M 24.81% | -19.825M 36.68% | -22.624M 32.04% | -22.771M 91.70% | -24.169M -12.73% | -24.446M -23.31% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -2.19 -434.15% | -0.44 | -1.75 | -394.60% |
| Q1 2025 Q2Q % growth | -0.26 42.22% | -0.23 | -0.03 | -12.62% |
| Q4 2024 Q2Q % growth | -0.44 -12.82% | -0.29 | -0.15 | -52.48% |
| Q3 2024 Q2Q % growth | -0.40 18.37% | -0.41 | 0.01 | 1.46% |
| Q2 2024 Q2Q % growth | -0.41 8.89% | -0.42 | 0.01 | 2.83% |
| Q1 2024 Q2Q % growth | -0.45 -4.65% | -0.38 | -0.07 | -17.69% |
| Q4 2023 Q2Q % growth | -0.39 25.00% | -0.51 | 0.12 | 23.28% |
| Q3 2023 Q2Q % growth | -0.49 22.22% | -0.47 | -0.02 | -3.54% |
| Q2 2023 Q2Q % growth | -0.45 22.41% | -0.44 | -0.01 | -3.06% |
| Q1 2023 Q2Q % growth | -0.43 29.51% | -0.39 | -0.04 | -11.12% |
| Q4 2022 Q2Q % growth | -0.52 -8.33% | -0.61 | 0.09 | 14.55% |
| Q3 2022 Q2Q % growth | -0.63 -26.00% | -0.61 | -0.02 | -2.68% |
| Q2 2022 Q2Q % growth | -0.58 -16.00% | -0.67 | 0.09 | 12.79% |
| Q1 2022 Q2Q % growth | -0.61 8.96% | -0.52 | -0.09 | -17.76% |
| Q4 2021 Q2Q % growth | -0.48 99.78% | -0.57 | 0.09 | 15.99% |
| Q3 2021 Q2Q % growth | -0.50 | -0.63 | 0.13 | 20.47% |
| Q2 2021 Q2Q % growth | -0.50 | -0.51 | 0.01 | 1.48% |
| Q1 2021 Q2Q % growth | -0.67 | -0.63 | -0.04 | -6.42% |
| Q4 2020 Q2Q % growth | -217.49 | -4.44 | -213.05 | -4,797.72% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 18.79% | 63.17% | -76.42% | -92.56% |
| Revenue | N/A | N/A | N/A | N/A |